Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years Old Children
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The aim of this study was to investigate the occurrences of respiratory symptoms risk factors and abnormalities in lung function in young children (3-6 years old) with hemato-oncologic diseases at presentation (before treatment) and up to 3 years follow-up (study period).
| Condition |
|---|
|
Acute Lymphoblastic Leukemia Acute Myeloblastic Leukemia Solid Tumors, Hodgkin's Disease Non-Malignant |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Retrospective |
| Official Title: | Pulmonary Function at Presentation and Follow-up in Hemato-Oncology 3-7 Years |
| Enrollment: | 35 |
| Study Start Date: | October 2005 |
| Study Completion Date: | October 2006 |
| Groups/Cohorts |
|---|
|
1
all were in a single group
|
Detailed Description:
Pulmonary function tests (PFTs) are a part of the routine follow-up of patients receiving anti-cancer treatment. Treatment is frequently associated with diverse pulmonary damage which may become functionally and clinically evident many years later. PFTs may help to quantify the damage in the lungs; help to evaluate the point at which lung function deviates from normal to allow early intervention before irreversible lung damage occurs and thereby to reduce morbidity and mortality.
Reliable PFTs in the preschool age have traditionally been difficult to perform, but recent publications have demonstrated that the majority of preschool children can produce reproducible forced expiratory flow volume (FEVC) curves with proper coaching techniques. This recent development may enable studying the long term effect (years) of treatment on lung function in young children suffering from hemato-oncologic diseases.
Eligibility| Ages Eligible for Study: | 3 Years to 7 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
All pediatric patients (age 3-7 years) with hemato-onclogic diseases that were treated at the Hemato-Oncology Department, and were sent to the pediatric pulmonary unit at the Safra children's hospital, Sheba medical center, Ramat-Gan, Israel, to perform lung function tests, as a part of a 3-year follow-up study.
Inclusion Criteria:
- All pediatric patients (age 3-7 years) with hemato-onclogic diseases that were treated at the Hemato-Oncology Department, and were sent to the pediatric pulmonary unit.
Contacts and Locations| Israel | |
| Sheba Medical CenterPediatric pulmonary unit, Pulmonary function laboratory | |
| Ramat-Gan, Ramat Gan, Israel, 52621 | |
| Principal Investigator: | Ori Efrati, MD | Sheba Medical Center |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00552825 History of Changes |
| Other Study ID Numbers: | SHEBA-05-3889-OE-CTIL, Observational |
| Study First Received: | November 1, 2007 |
| Last Updated: | November 1, 2007 |
| Health Authority: | Israel: Israeli Health Ministry Pharmaceutical Administration |
Keywords provided by Sheba Medical Center:
|
acute lymphoblastic leukemia long-term lung function |
Additional relevant MeSH terms:
|
Hodgkin Disease Leukemia Leukemia, Lymphoid Precursor Cell Lymphoblastic Leukemia-Lymphoma Leukemia, Myeloid, Acute Leukemia, Myeloid Lymphoma |
Neoplasms by Histologic Type Neoplasms Lymphoproliferative Disorders Lymphatic Diseases Immunoproliferative Disorders Immune System Diseases |
ClinicalTrials.gov processed this record on May 23, 2013